AMNEAL PHARMACEUTICALS, INC. By Chris Wack
Amneal Pharmaceuticals shares were up 9% after the Food and Drug Administration approved an abbreviated new drug application for over-the-counter Naloxone Hydrochloride nasal spray.
The stock, trading at $5.89 midday, hit its 52-week high of $6.46 on March 19.
The New Jersey-based pharmaceutical company said its Naloxone HCI nasal spray is a generic equivalent to OTC NARCAN HCI nasal spray, a medication used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.
The FDA approval means that Naloxone is now available for purchase.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
04-24-24 1234ET
